Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells

(2021) Rubia Isler Mancuso et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diffuse Large B-Cell Lymphoma

(2021) Laurie H. Sehn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

(2021) Man Chun John Ma et al.   HAEMATOLOGICA

The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential

(2021) Takashi Watanabe   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

(2021) Juan Garcia Valero et al.   LEUKEMIA

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

(2021) Tiffany Davia Ricketts et al.   Frontiers in Immunology

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy

(2021) Elise A Chong et al.   BLOOD

The Role of Tumor-Associated Macrophages in Hematologic Malignancies

(2021) Emanuele Cencini et al.   Cancers

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

(2020) Ajay K Gopal et al.   CLINICAL CANCER RESEARCH

Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization

(2020) Caitlin D. Lemke-Miltner et al.   JOURNAL OF IMMUNOLOGY

Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

(2020) Pablo Mozas et al.   Blood Cancer Journal

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

(2020) Lorenzo Galluzzi et al.   Journal for ImmunoTherapy of Cancer

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

(2020) Matthew J. Frank et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mantle cell lymphoma

(2020) Sergio Cortelazzo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

(2020) Kathryn M. Cappell et al.   JOURNAL OF CLINICAL ONCOLOGY

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

(2020) Franck Morschhauser et al.   LANCET ONCOLOGY

Targeting immunogenic cell death in cancer

(2020) Asma Ahmed et al.   Molecular Oncology

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

(2020) Marco Ladetto et al.   Lancet Haematology

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

(2019) Antonin Papin et al.   LEUKEMIA

Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma

(2019) Ciara L. Freeman et al.   BLOOD

Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia

(2019) Priyanka Banerjee et al.   Cancer Immunology Research

Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine

(2019) Caterina Lapenta et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Diversification of Cell Death and Immunity: Memento Mori

(2019) Arnaud J. Legrand et al.   MOLECULAR CELL

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity

(2019) Suresh de Silva et al.   Cancer Immunology Research

Pathogenesis of follicular lymphoma

(2018) Tracy Lackraj et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Radiotherapy of relapse-refractory follicular lymphoma

(2018) É. Grignano et al.   Cancer Radiotherapie

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Eradication of spontaneous malignancy by local immunotherapy

(2018) Idit Sagiv-Barfi et al.   Science Translational Medicine

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

(2018) Anna H. Turaj et al.   Scientific Reports

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

(2018) Franck Morschhauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

(2018) Matthew J. Frank et al.   Cancer Discovery

B cell lymphomas present immunoglobulin neoantigens

(2018) Michael S. Khodadoust et al.   BLOOD

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

A drug development perspective on targeting tumor-associated myeloid cells

(2017) Meher Majety et al.   FEBS Journal

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

(2017) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

OX40: Structure and function – What questions remain?

(2017) Jane Willoughby et al.   MOLECULAR IMMUNOLOGY

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens

(2017) Michael S. Khodadoust et al.   NATURE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

More insights into the pharmacological effects of artemisinin

(2017) Abdelmajid Zyad et al.   PHYTOTHERAPY RESEARCH

Human Tumor Antigens Yesterday, Today, and Tomorrow

(2017) Olivera J. Finn   Cancer Immunology Research

Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy

(2017) B. Montico et al.   OncoImmunology

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

(2016) V. Jurinovic et al.   BLOOD

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation

(2016) Vinit Kumar et al.   IMMUNITY

NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients

(2016) Caterina Lapenta et al.   JOURNAL OF IMMUNOLOGY

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice

(2016) Stefanie N. Linch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

(2016) Katelyn T. Byrne et al.   Cell Reports

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma

(2015) I. Sagiv-Barfi et al.   BLOOD

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

(2015) D. M. Kurtz et al.   BLOOD

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

(2015) J. R. Baird et al.   CANCER RESEARCH

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

(2015) Kobe Reynders et al.   CANCER TREATMENT REVIEWS

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN

(2015) Burcu Temizoz et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

(2015) Jia Ruan et al.   NEW ENGLAND JOURNAL OF MEDICINE

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

(2015) Michael R. Green et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patrolling monocytes control tumor metastasis to the lung

(2015) R. N. Hanna et al.   SCIENCE

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Anatomy of a Discovery: M1 and M2 Macrophages

(2015) Charles Dudley Mills   Frontiers in Immunology

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation

(2014) Jia Xue et al.   IMMUNITY

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

(2014) Ronald Levy et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cellular and molecular origin of tumor-associated macrophages

(2014) R. A. Franklin et al.   SCIENCE

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

(2013) Thomas E. Witzig et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

(2013) Felix Klug et al.   CANCER CELL

Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

(2013) K. Song et al.   CANCER RESEARCH

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

(2013) J. Fourcade et al.   CANCER RESEARCH

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Cyclic Dinucleotides and the Innate Immune Response

(2013) Olga Danilchanka et al.   CELL

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis

(2012) Simon Yona et al.   IMMUNITY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma

(2011) Stephen J. Schuster et al.   JOURNAL OF CLINICAL ONCOLOGY

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death

(2010) R. Zappasodi et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction

(2010) J. Rolf et al.   JOURNAL OF IMMUNOLOGY

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Prolonged Antigen Presentation Is Required for Optimal CD8+ T Cell Responses against Malaria Liver Stage Parasites

(2010) Ian A. Cockburn et al.   PLoS Pathogens

Memories that last forever: strategies for optimizing vaccine T-cell memory

(2009) J. D. Ahlers et al.   BLOOD

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Differential Cytokine Production and Bystander Activation of Autoreactive B Cells in Response to CpG-A and CpG-B Oligonucleotides

(2009) A. M. Avalos et al.   JOURNAL OF IMMUNOLOGY

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells

(2009) Martin Guimond et al.   NATURE IMMUNOLOGY

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

(2008) M. Di Nicola et al.   BLOOD

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL

Memory CD8 T-cell compartment grows in size with immunological experience

(2008) Vaiva Vezys et al.   NATURE

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD